2020
DOI: 10.2147/cmar.s258016
|View full text |Cite
|
Sign up to set email alerts
|

<p>Association Between Intermediate-Acting Neuromuscular-Blocking Agents and Short-Term Postoperative Outcomes in Patients with Gastric Cancer</p>

Abstract: This study examined whether different neuromuscular-blocking agents (NMBAs) work differently on the short-term outcomes of gastric cancer patients in terms of laboratory test results and severity of postoperative illness, and whether the effect is dose-related. Patients and Methods: Data of 1643 adult patients receiving gastric cancer surgery were analyzed by employing generalized linear models (GLMs), to explore the effects of different NMBAs on neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PL… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 34 publications
0
1
0
Order By: Relevance
“…For example, Ou et al (2022) used pretreatment hematological parameters of CC patients to build an ML model to predict LNM in patients and built a Cforest model with a performance AUC of only 0.620. In addition, uncontrollable factors such as drugs and inflammation can affect the stability of hematological indicators, and different testing reagents and equipment can cause bias in the test results ( Niu et al, 2020 ), all of which are not conducive to the popularization of this method. Arezzo et al (2023) established LR and XGBoost models to predict LNM in patients with advanced CC using clinical data and pelvic MRI as the characteristic parameters, and the results showed that the XGBoost model demonstrated a better predictive performance (89% accuracy, 83% precision, 78% recall, and AUC 0.79).…”
Section: Discussionmentioning
confidence: 99%
“…For example, Ou et al (2022) used pretreatment hematological parameters of CC patients to build an ML model to predict LNM in patients and built a Cforest model with a performance AUC of only 0.620. In addition, uncontrollable factors such as drugs and inflammation can affect the stability of hematological indicators, and different testing reagents and equipment can cause bias in the test results ( Niu et al, 2020 ), all of which are not conducive to the popularization of this method. Arezzo et al (2023) established LR and XGBoost models to predict LNM in patients with advanced CC using clinical data and pelvic MRI as the characteristic parameters, and the results showed that the XGBoost model demonstrated a better predictive performance (89% accuracy, 83% precision, 78% recall, and AUC 0.79).…”
Section: Discussionmentioning
confidence: 99%